Market Place
Sourcing Support
All News #Library
Biotech
PharmaEssentia Reveals Japan Approval For High-Dose BESREMi
02 Mar 2026 //
PHARMIWEB
Pharmaessentia To Build U.S. Plant In Puerto Rico For Besremi®
09 Feb 2026 //
PHARMIWEB
PharmaEssentia’s BESREMi Added to Guidelines for Thrombocythemia
27 Jan 2026 //
BUSINESSWIRE
FDA Sets August 30, 2026 PDUFA Goal Date For Ropeginterferon
13 Jan 2026 //
PHARMIWEB
PharmaEssentia Reports Positive Phase 2b ET Study Data
12 Jan 2026 //
PHARMIWEB
PharmaEssentia`s Phase 3 SURPASS-ET Trial Published in The Lancet
24 Nov 2025 //
BUSINESSWIRE
ICC Tribunal Rules In Favor Of AOP Health In BESREMi Case
17 Feb 2025 //
BUSINESSWIRE
PharmaEssentia Phase 3 Data For Ropeginterferon In Thrombocythemia
07 Jan 2025 //
BUSINESSWIRE
PharmaEssentia Enters Into Global License Agreement With WuXi Biologics
03 Oct 2023 //
BUSINESSWIRE
Study Shows Ropeginterferon Alfa-2b-njft Is a Cost-Effective Treatment Option for Polycythemia Vera
04 Aug 2023 //
BUSINESSWIRE
NCCN Clinical Practice Guidelines in Oncology Updated to Recommend BESREMi
23 May 2023 //
BUSINESSWIRE
PharmaEssentia Initiates Ph 3b Trial of Ropeginterferon alfa-2b-njft
03 May 2023 //
BUSINESSWIRE
PharmaEssentia Initiates Ph2b Trial of ropeginterferon alfa-2b-njft for ET
23 Feb 2023 //
BUSINESSWIRE
Taiwan`s PharmaEssentia opens new R&D facility in US
10 Jan 2023 //
BIOSPECTRUM ASIA
Copyright © 2026 LePro PharmaCompass OPC Private Limited, All rights reserved.